Stellantis introduced early Monday that it plans a second U.S. battery plant to assist assist American EV manufacturing.
With a memorandum of understanding signed between Stellantis and Samsung SDI Monday, the businesses search to begin manufacturing on the facility in 2027 and “an preliminary annual manufacturing capability of 34 gigawatt-hours.” However the location stays undisclosed and “at the moment beneath assessment,” in accordance with a launch.
The second battery plant will fall beneath the identical StarPlus Vitality three way partnership as its first U.S. facility at the moment being in-built Kokomo, Indiana and as a consequence of ramp up in early 2025.
Moreover, Stellantis reported that the Indiana plant will goal for an annual manufacturing of 33 gigawatt-hours, up from 23 when the challenge was introduced.
STLA Massive platform – Stellantis EVs
Stellantis’ different proposed battery plant, a three way partnership with LG Vitality Answer, had been stalled till earlier this month over points wherein “the Canadian authorities has not delivered on what was agreed to.”
As of July 5, the businesses reported the challenge was again on, with the plant as a consequence of begin manufacturing in 2024, ramping as much as an annual output of greater than 45 gigawatt-hours.
That 4.5-million-square-foot manufacturing unit was beforehand as a consequence of be accomplished by the top of 2023. The location may also be serving as a know-how middle for cell, module, and battery-pack growth for EVs, hybrids, and plug-in hybrids, however the firm hasn’t but commented on how this delay may have an effect on these plans.
Jeep Recon
Stellantis additionally hasn’t but offered an replace on whether or not this impacts the timeline for the launch of upcoming EVs, probably together with the Ram 1500 REV electrical truck, a Dodge electrical muscle automobile, and a Jeep Recon that would act as a completely electrical “brother” to the Wrangler.
Samsung SDI cells have precedent in Stellantis’ U.S. EV lineup. The unique Fiat 500e that first arrived for restricted U.S. sale a decade in the past was outfitted with cells from that firm.
